Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds.
Using a plaque reduction assay, we determined the 50% effective doses of six antiviral compounds against low- and high-passage viruses of the KMcC and Oka strains of varicella-zoster virus vaccine. The potency, as indicated by the ranges of 50% effective doses (micrograms per milliliter) of the antiviral compounds, in decreasing order was as follows: (E)-5-(2-bromovinyl)-2'-deoxyuridine, 0.0007 to 0.0035; 1-(2'-flouro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine, 0.0063 to 0.0091; aphidicolin, 0.092 to 0.180; acyclovir, 0.79 to 1.81; vidarabine, 0.62 to 2.10; and phosphonoformic acid, 8.18 to 16.4. Susceptibility to the various antiviral compounds was independent of passage level or strain. These data, along with the available in vivo data, indicate that varicella-zoster virus vaccine infections requiring antiviral therapy most probably would be treated as effectively as would natural varicella infections.
D000998:Antiviral Agents / Q000494:pharmacology*; D005333:Fetus; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008168:Lung; D010948:Viral Plaque Assay; D014765:Viral Vaccines; D014776:Virus Cultivation; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D014765:Viral Vaccines